title: Antikaliuretic action of trimethoprim is minimized by raising urine pH.
abstract: This study was designed to test the hypothesis that the antikaliuresis caused by trimethoprim could be diminished by alkalinizing the luminal fluid in the CCD, thereby converting trimethoprim from its cationic, active form to an electroneutral, inactive, form. Trimethoprim-induced inhibition of transepithelial Na+ transport was examined in A6 distal nephron cells by analysis of short circuit current. The voltage-dependence of the trimethoprim-induced block of Na+ channels was examined with patch clamp recordings of A6 cells. The antikaliuretic effect of trimethoprim was examined in vivo in rats pretreated with deoxycorticosterone and with NH4Cl to lower urine pH, and in rats also receiving acetazolamide to raise urine pH. We found that the concentration of trimethoprim required to inhibit the amiloride sensitive component of short circuit current by 50% (IC50) was 340 microM (at pH 8.2) and 50 microM (at pH 6.3). The IC50S of protonated trimethoprim were similar (34 microM at pH 8.2 and 45 microM at pH 6.3). The mean time open for the high selectivity, Na+ channel was reduced from 1679 +/- 387 msec to 502 +/- 98 msec with addition of 10-5 M trimethoprim to patch pipette solution at the resting membrane potential (-Vpipette = 0 mV). further decreases in mean time open were observed as -Vpipette was reduced (that is, apical membrane hyperpolarization) to -40 mV (mean time open = 217 +/- 85 msec) and to -80 mV (mean time open = 69 +/- 13 msec). In vivo, trimethoprim caused a > 50% reduction in potassium (K+) excretion due primarily to a fall in the [K+] in the lumen of the terminal CCD. This effect of trimethoprim was markedly attenuated in an alkaline urine induced by acetazolamide. We conclude that it is the charged, protonated species of trimethoprim which blocks epithelial Na+ channels. Increasing urinary pH decreases the concentration of the charged species of trimethoprim and minimizes its antikaliuretic effect.
authors.affiliation: Department of Medicine, St. Michael's Hospital, University of Toronto, Canada.
authors.forename: M
authors.initials: M
authors.lastname: Schreiber
authors.forename: L E
authors.initials: LE
authors.lastname: Schlanger
authors.forename: C B
authors.initials: CB
authors.lastname: Chen
authors.forename: M
authors.initials: M
authors.lastname: Lessan-Pezeshki
authors.forename: M L
authors.initials: ML
authors.lastname: Halperin
authors.forename: A
authors.initials: A
authors.lastname: Patnaik
authors.forename: B N
authors.initials: BN
authors.lastname: Ling
authors.forename: T R
authors.initials: TR
authors.lastname: Kleyman
mesh_terms: D000818:Animals; D000892:Anti-Infective Agents, Urinary / Q000008:administration & dosage*; D006863:Hydrogen-Ion Concentration; D007274:Injections, Intraperitoneal; D007684:Kidney Tubules / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D008564:Membrane Potentials; D018408:Patch-Clamp Techniques; D011188:Potassium / Q000652:urine*; D015221:Potassium Channels / Q000187:drug effects / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D026941:Sodium Channel Blockers; D015222:Sodium Channels / Q000378:metabolism*; D014295:Trimethoprim / Q000008:administration & dosage*
chemical_list: D000892:Anti-Infective Agents, Urinary; D015221:Potassium Channels; D026941:Sodium Channel Blockers; D015222:Sodium Channels; D014295:Trimethoprim; D011188:Potassium